Legal, PR Efforts Ramp Up To Target J&J On Vaginal Mesh Device Issues
This article was originally published in The Gray Sheet
Executive Summary
The Corporate Action Network has launched a new website intended to shame the firm for practices tied to its withdrawn pelvic mesh implant devices, while requesting a Department of Justice investigation into the firm’s document-destruction activities and hatching plans to disrupt J&J’s annual shareholder meeting.
You may also be interested in...
J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.
J&J/Ethicon Begins Worldwide Withdrawal Of Vaginal Mesh Products
Firm is stopping sales of four of its vaginal mesh products in the face of over 1,000 product liability lawsuits and FDA requirements for post-market safety and efficacy studies.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”